Gustave Roussy Immune Score (GRIm-Score) as a Prognostic and Predictive Score in Metastatic Colorectal Cancer.

Autor:	Cotan H; Oncology, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU., Iaciu C; Oncology, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU., Radu E; Gastroenterology, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU., Niculae T; Nephrology, Nephrology Hospital Dr. Carol Davila, Bucharest, ROU., Rosu OA; Oncology, Elias Emergency University Hospital, Bucharest, ROU., Nitipir C; Oncology, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Apr 24; Vol. 16 (4), pp. e58935. Date of Electronic Publication: 2024 Apr 24 (Print Publication: 2024).
DOI:	10.7759/cureus.58935
Abstrakt:	Introduction: Metastatic colorectal cancer (mCRC) presents significant clinical challenges due to its heterogeneous nature and variable treatment responses. The Gustave Roussy Immune Score (GRIm-Score) has emerged as a potential biomarker for prognostication and prediction in mCRC, although its precise role remains under investigation. Methods: We conducted a retrospective study that included 173 patients diagnosed with mCRC. The patients were treated in the first line with 5-fluorouracil (5-FU)-based chemotherapy (CHT) and a molecular agent based on their eligibility. We assessed the overall survival (OS) time, progression-free survival (PFS) time, and the overall response rate (ORR), utilizing the GRIm-score measured at baseline (referred to as GRImT0) and the variance between GRImT0 and the GRIm score measured three months after treatment initiation (referred to as GRIm∆). We also performed a subgroup analysis based on the type of treatment received. Results: Our analysis revealed that the GRIm-Score holds promise as a prognostic marker in mCRC, with high scores correlating with poorer survival outcomes. However, in the subgroup analysis, this prognostic value remained relevant only for patients treated with CHT and anti-EGFR (epidermal growth factor receptor) agents, such as cetuximab and panitumumab. GRIm-Score exhibited no predictive value irrespective of the treatment received. Conclusion: The GRIm-Score shows potential as a prognostic mCRC, although we believe that this potential is limited. Integration of the GRIm-Score into clinical practice should be done with caution and is not recommended at this time. However, further research is needed to fully elucidate its clinical utility and optimize its incorporation into routine clinical care. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Cotan et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu